Английская Википедия:Benralizumab

Материал из Онлайн справочника
Перейти к навигацииПерейти к поиску

Шаблон:Short description Шаблон:Drugbox

Benralizumab, sold under the brand name Fasenra, is a monoclonal antibody directed against the alpha chain of the interleukin-5 receptor (CD125). It was developed by MedImmune for the treatment of asthma.[1][2]

Two phase III clinical trials of benralizumab reported meeting their primary endpoints in 2016.[3][4] It was approved by the US Food and Drug Administration in November 2017 for the treatment of severe eosinophilic asthma.[5] It was granted designation as an orphan drug by the Food and Drug Administration for treatment of eosinophilic oesophagitis in August 2019.[6]

Common adverse effects include injection site reactions, which were reported in 2.2% of patients (vs. 1.9% for placebo) in clinical trials.[7]

References

Шаблон:Reflist

External links

Шаблон:Monoclonals for immune system Шаблон:Interleukin receptor modulators Шаблон:AstraZeneca Шаблон:Portal bar


Шаблон:Monoclonal-antibody-stub Шаблон:Respiratory-system-drug-stub